GENTAUR Europe BVBA
Genprice Inc, Logistics
Serbia, 
Macedonia, 
Montenegro, 
Croatia: 
GENTAUR Romania
GENTAUR Greece 
Medicament for the treatment of hepatitis C, developed by Gilead Sciences, received a positive evaluation by the Administration Food and Drug Administration in the U.S..
A positive response by the administration due to the success that the medicament is accomplished by treatment of the disease - more patients are cured in a shorter period of time compared with other drugs in the market.
Studies have shown that adding the drug to Sofosbuvir other prescribed medication is able to cure 90% of patients within 12 weeks, reports the Associated Press. So far no evidence of side effects associated with taking Sofosbuvir.
Since 1986 suffering from hepatitis C treated with interferon alpha protein. However, it is not suitable for everybody, and the positive outcome of the treatment was observed in less than half of the patients who take it.
On the other hand, side effects include depression, symptoms resemble those of the flu, such as fever, fatigue and headache. In some cases, they may even be exacerbated to the extent that may be necessary to slow or stop the treatment.
In 2011, the Administration has approved two drugs that can be used as an add-on to treat the most common type of hepatitis C. Studies have found that the drugs increase the number of patients cured by 65 - 75% of. Recently, however, pharmaceutical companies insist on medications that do not contain interferon.
Hepatitis C is a blood disorder that causes inflammation of the liver. Around 70-80% of people with hepatitis C do not notice any symptoms.
When they are present include: pain in the right upper abdomen, dark urine, fever, jaundice, nausea and vomiting. People with acute hepatitis C may develop a chronic infection.
Chronic hepatitis C can cause cirrhosis of the liver and is a leading factor in the development of liver cancer cherry.
